leisure time -WSS

leisure time

author：leisure time 2025-09-27 22:48:25 - browse：1

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

focus

explore

WSS

Results on Novartis prostate cancer therapy could expand its use

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Why a market frenzy over new weight loss drugs defies logic

Ohio train derailment: Experts on toxic chemical risks

'Vaccine

focus

leisure time

focus

Alkermes shareholders re

FDA clears Verve to begin U.S. study of gene

Alkermes shareholders re

Health tech investors get more selective as pandemic boom fades

Walensky prepares to leave CDC — and Congress — behind

Doctor of U.S. President Joe Biden says he is fit for duty

Alkermes shareholders re

CDC advisory group OKs chikungunya vaccine

State Dept. review finds Biden bears some blame for Afghanistan failures

Children’s Hospital revives plan for pedestrian bridge

knowledge

'Vaccine

Are embryos people? Reproductive medicine's future depends on the answer

Study fuels hope CAR

STAT Summit: The economic case for universal basic health care

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: Meghan O’Rourke on making chronic illness visible

Wikipedia

hotspot

explore

hotspot